Glenmark Pharmaceuticals today said it has received nod from the US health regulator to market adapalene gel, used in treating acne, in the American market.
The approval was granted to its US subsidiary, Glenmark Generics Inc, for the Abbreviated New Drug Application for adapalene gel in strength of 0.1 per cent by the US Food and Drugs Administration, the company said in a statement.
Distribution and marketing of the product in the US market will start soon, it added.
Adapalene gel is the generic equivalent of Galderma's 'Differin' gel, which according to IMS Health, generated sales worth around $84 million in 2009-10.
"Today's approval expands the volume of the company's portfolio to include a total of 15 semi solid products authorised for distribution," the company said.
The company's current portfolio consists of 55 products authorised for distribution in the US market and has over 50 ANDA's approvals pending with the USFDA.
Shares of Glenmark were trading at Rs 274.50 a piece on the Bombay Stock Exchange in late afternoon trade, up 1.74 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app